BR9907236A - Inibidores de canais de potássio - Google Patents
Inibidores de canais de potássioInfo
- Publication number
- BR9907236A BR9907236A BR9907236-0A BR9907236A BR9907236A BR 9907236 A BR9907236 A BR 9907236A BR 9907236 A BR9907236 A BR 9907236A BR 9907236 A BR9907236 A BR 9907236A
- Authority
- BR
- Brazil
- Prior art keywords
- optionally substituted
- alkyl
- carbocycloalkyl
- heterocyclyl
- potassium channel
- Prior art date
Links
- 102000004257 Potassium Channel Human genes 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 108020001213 potassium channel Proteins 0.000 title abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 101100495913 Arabidopsis thaliana CHR17 gene Proteins 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000001072 heteroaryl group Chemical group 0.000 abstract 4
- 125000003107 substituted aryl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/12—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings
- C07C311/13—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing rings the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/36—Radicals substituted by singly-bound nitrogen atoms
- C07D213/40—Acylated substituent nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
- C07D317/60—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Magnetic Heads (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyrrole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- External Artificial Organs (AREA)
- Seasonings (AREA)
- Sorption Type Refrigeration Machines (AREA)
Abstract
"INIBIDORES DE CANAIS DE POTáSSIO". Os compostos de fórmula geral (I), na qual t é 1 ou 2; A e B são cada um H, ou considerados juntos formam uma ligação entre os carbonos substituidos; R1 é H, alquila, ou é selecionado do grupo consistindo em uma arila opcionalmente substituída, uma heteroarila opcionalmente substituída, uma heterociclila opcionalmente substituída e uma carbocicloalquila opcionalmente substituída; Y2 é (CH2)q, HC=CH ou NH, w é 0, 1, ou 2, q é 0, 1 ou 2; X2 é C=O, C=S, ou SO2; R3 é H, alquila, uma arila opcionalmente substituída, uma aralquila opcionalmente substituída, uma heteroarila opcionalmente substituída, uma heteroalquila opcionalmente substituída; um heterociclo opcionalmente substituído, uma heterociclila opcionalmente substituída, uma carbocicloalquila opcionalmente substituída, ou um alquileno- (amino substituído) ; Z é, em particular, H ou OH; R2 é selecionado do grupo consistindo em H, alquila, uma arila opcionalmente substituída, uma aralquila opcionalmente substituída, uma heteroarila opcionalmente substituída, uma heterociclila opcionalmente substituída, uma heteroalquila opcionalmente substituída, uma carbocicloalquila opcionalmente substituída, Ra-O-, e RbRc-N-; Y1 é (CH2)p, CHR17(CH2)o, HC=CH ou etinila, p é 0, 1, 2 ou 3, o é 0, 1 ou 2; X1 é C=O, C=S, SO2 ou (CH2) n, n é 0, 1, ou 2; R4 é H, alquila, uma arila opcionalmente substituída, uma aralquila opcionalmente substituída, uma heteroarila opcionalmente substituída, uma heteroalquila opcionalmente substituída, um heterociclo opcionalmente substituído, uma heterociclila opcionalmente substituída, uma carbocicloalquila opcionalmente substituída, ou um alquileno- (amino substituído) ; ou os sais ou prodrogas farmaceuticamente aceitáveis dos mesmos são úteis como inibidores de canais de potássio e especialmente úteis para o tratamento de arritmias cardíacas e distúrbios proliferativos celulares.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7271998P | 1998-01-27 | 1998-01-27 | |
PCT/US1999/001663 WO1999037607A1 (en) | 1998-01-27 | 1999-01-27 | Potassium channel inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BR9907236A true BR9907236A (pt) | 2002-01-22 |
Family
ID=22109343
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR9907236-0A BR9907236A (pt) | 1998-01-27 | 1999-01-27 | Inibidores de canais de potássio |
Country Status (21)
Country | Link |
---|---|
US (1) | US6333337B1 (pt) |
EP (1) | EP1051394B1 (pt) |
JP (1) | JP2002501041A (pt) |
KR (1) | KR20010034377A (pt) |
CN (1) | CN1294577A (pt) |
AT (1) | ATE265426T1 (pt) |
AU (1) | AU745845B2 (pt) |
BR (1) | BR9907236A (pt) |
CA (1) | CA2317457A1 (pt) |
DE (1) | DE69916792D1 (pt) |
HU (1) | HUP0101269A3 (pt) |
ID (1) | ID25853A (pt) |
IL (1) | IL137219A0 (pt) |
NO (1) | NO20003600L (pt) |
NZ (1) | NZ505666A (pt) |
PL (1) | PL341859A1 (pt) |
RU (1) | RU2218330C2 (pt) |
TR (1) | TR200002191T2 (pt) |
TW (1) | TW542823B (pt) |
WO (1) | WO1999037607A1 (pt) |
ZA (1) | ZA99550B (pt) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6333349B1 (en) * | 1997-02-26 | 2001-12-25 | Aventis Pharma Deutschland Gmbh | Sulfonamide-substituted fused 7-membered ring compounds, their use as a medicament, and pharmaceutical preparations comprising them |
WO2000012077A1 (en) | 1998-09-01 | 2000-03-09 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
JP2003510257A (ja) * | 1999-09-22 | 2003-03-18 | コグネティックス・インコーポレイテッド | カッパ−コノトキシンpviiaの使用 |
AU781365B2 (en) * | 1999-12-21 | 2005-05-19 | Icagen, Inc. | Potassium channel inhibitors |
US6566380B2 (en) * | 2000-07-25 | 2003-05-20 | Icagen, Inc. | Potassium channel inhibitors |
US6620849B2 (en) * | 2000-07-26 | 2003-09-16 | Icafen, Inc. | Potassium channel inhibitors |
DE10059418A1 (de) | 2000-11-30 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, meta-substituierte Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10060807A1 (de) | 2000-12-07 | 2002-06-20 | Aventis Pharma Gmbh | Ortho, ortho-substituierte stickstoffhaltige Bisarylverbindungen, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
DE10061876A1 (de) * | 2000-12-12 | 2002-06-20 | Aventis Pharma Gmbh | Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
US6849634B2 (en) | 2000-12-21 | 2005-02-01 | Icagen | Potassium channel inhibitors |
DE10121003A1 (de) | 2001-04-28 | 2002-12-19 | Aventis Pharma Gmbh | Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen |
JP4511189B2 (ja) | 2002-02-12 | 2010-07-28 | セレクトリコン アーベー | センサーの周囲の溶液環境を迅速に変化させるシステム及び方法 |
US7470518B2 (en) | 2002-02-12 | 2008-12-30 | Cellectricon Ab | Systems and method for rapidly changing the solution environment around sensors |
US20030199578A1 (en) * | 2002-04-19 | 2003-10-23 | Turner Sean C. | Naphthalene amides as potassium channel openers |
WO2003095420A1 (en) * | 2002-05-08 | 2003-11-20 | Bayer Healthcare Ag | Hydroxy tetrahydro-naphthalenylurea derivatives |
WO2004052846A1 (en) * | 2002-12-06 | 2004-06-24 | Bayer Healthcare Ag | Tetrahydro-naphthalene derivatives |
JP4440113B2 (ja) * | 2002-12-09 | 2010-03-24 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | バニロイド受容体アンタゴニストとしてのテトラヒドロ−ナフタレン誘導体 |
GB0315950D0 (en) | 2003-06-11 | 2003-08-13 | Xention Discovery Ltd | Compounds |
US7662821B2 (en) | 2003-10-08 | 2010-02-16 | Bayer Schering Pharma Ag | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
ES2279454T3 (es) | 2003-10-08 | 2007-08-16 | Bayer Schering Pharma Aktiengesellschaft | Derivados de tetrahidronaftaleno sustituidos con 1-amino-2-oxi, procedimientos para su preparacion y su utilizacion como anti-inflamatorios. |
US7638515B2 (en) | 2003-10-08 | 2009-12-29 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
US20080153859A1 (en) | 2004-04-05 | 2008-06-26 | Hartmut Rehwinkel | Multiply-substituted tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents |
GB0412986D0 (en) | 2004-06-10 | 2004-07-14 | Xention Discovery Ltd | Compounds |
US7576212B2 (en) | 2004-12-09 | 2009-08-18 | Xention Limited | Thieno[2,3-B] pyridines as potassium channel inhibitors |
DE102005017316A1 (de) * | 2005-04-14 | 2006-10-19 | Schering Ag | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
GB0525164D0 (en) | 2005-12-09 | 2006-01-18 | Xention Discovery Ltd | Compounds |
EP1834948A1 (de) | 2006-03-15 | 2007-09-19 | Bayer Schering Pharma Aktiengesellschaft | Tetrahydronaphthalinderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer |
CA2648196A1 (en) * | 2006-04-14 | 2007-10-25 | Novartis Ag | Use of biarylcarboxamides in the treatment of hedgehog pathway-related disorders |
DE102006019589A1 (de) * | 2006-04-27 | 2007-10-31 | Sanofi-Aventis Deutschland Gmbh | Inhibitoren des TASK-1 und Task-3 Ionenkanals |
SG174095A1 (en) * | 2006-08-23 | 2011-09-29 | Valeant Pharmaceuticals Int | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
BRPI0719590A2 (pt) * | 2006-11-28 | 2014-01-21 | Valeant Pharmaceuticals Int | Análogos de retigabina 1,4 diamino bicíclica como modulares de canal de potássio |
GB0815784D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
GB0815782D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
GB0815781D0 (en) | 2008-08-29 | 2008-10-08 | Xention Ltd | Novel potassium channel blockers |
GB201105659D0 (en) | 2011-04-01 | 2011-05-18 | Xention Ltd | Compounds |
NO3175985T3 (pt) | 2011-07-01 | 2018-04-28 | ||
JP2015504923A (ja) | 2012-01-27 | 2015-02-16 | ギリアード サイエンシーズ, インコーポレイテッド | 後期ナトリウムイオンチャネル遮断剤およびカリウムイオンチャネル遮断剤を使用する併用療法 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4005140A (en) | 1974-02-07 | 1977-01-25 | American Cyanamid Company | Ureidotetralin compounds |
US3953506A (en) | 1974-02-07 | 1976-04-27 | American Cyanamid Company | Ureidotetralin compounds |
GB1479544A (en) | 1974-02-07 | 1977-07-13 | American Cyanamid Co | 1,2,3,4-tetrahydro-1-naphthylurea derivatives their preparation and their use |
GB8707123D0 (en) | 1987-03-25 | 1987-04-29 | Pfizer Ltd | Antiarrhythmic agents |
US5006512A (en) | 1987-10-02 | 1991-04-09 | Tsuyoshi Ohnishi | Therapeutic usages of inhibitors for a potassium efflux channel |
IL88314A (en) | 1987-11-18 | 1994-05-30 | Tanabe Seiyaku Co | History of sulfonylamino indane, their preparation and pharmaceutical preparations containing them |
DK691488A (da) | 1987-12-14 | 1989-06-15 | Beecham Group Plc | Hidtil ukendte forbindelser |
US5242947A (en) | 1988-02-10 | 1993-09-07 | New York University | Use of polyamines as ionic-channel regulating agents |
DE3818245A1 (de) | 1988-05-28 | 1989-12-07 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln |
US5215985A (en) | 1990-07-20 | 1993-06-01 | E. R. Squibb & Sons, Inc. | Method for treating ischemic insult to neurons employing an ATP-sensitive potassium channel blocker |
ATE167473T1 (de) | 1990-08-20 | 1998-07-15 | Eisai Co Ltd | Sulfonamid-derivate |
US5401848A (en) | 1990-11-26 | 1995-03-28 | E. R. Squibb & Sons, Inc. | Indane and quinoline derivatives |
US5310932A (en) | 1991-04-15 | 1994-05-10 | E. R. Squibb & Sons, Inc. | Chromanyl substituted indole potassium channel openers |
US5234947A (en) | 1991-11-07 | 1993-08-10 | New York University | Potassium channel activating compounds and methods of use thereof |
US5356775A (en) | 1992-07-29 | 1994-10-18 | Brigham & Women's Hospital | Primary structure for functional expression from complementary DNA of a mammalian ATP-sensitive potassium channel |
US5328830A (en) | 1992-09-08 | 1994-07-12 | Miles Inc. | Potassium channel modulators |
US5374643A (en) | 1992-09-11 | 1994-12-20 | E. R. Squibb & Sons, Inc. | Aryl urea (thiourea) and cyanoguanidine derivatives |
US5453421A (en) | 1992-09-11 | 1995-09-26 | E. R. Squibb & Sons, Inc. | Aryl and heterocyclic substituted propenamide derivatives |
DE4302051A1 (de) | 1993-01-26 | 1994-07-28 | Thomae Gmbh Dr K | 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
GB9309716D0 (en) | 1993-05-12 | 1993-06-23 | Zeneca Ltd | Heterocyclic derivatives |
US5401758A (en) | 1993-10-07 | 1995-03-28 | Bristol-Myers Squibb Company | Pyridinyl cyanoguanidine compounds |
US5631275A (en) | 1993-12-30 | 1997-05-20 | Hoechst Aktiengesellschaft | Substituted benzenesulfonylureas and -thioureas, preparation processes and possible uses of pharmaceutical preparations based on these compounds |
FR2717805B1 (fr) | 1994-03-28 | 1996-05-10 | Rhone Poulenc Rorer Sa | Dérivés de 5H-indeno[1,2-b]pyrazine-2,3-dione, leur préparation et les médicaments les contenant . |
US5615460A (en) | 1994-06-06 | 1997-04-01 | The Procter & Gamble Company | Female component for refastenable fastening device having regions of differential extensibility |
ZA96211B (en) | 1995-01-12 | 1996-07-26 | Teva Pharma | Compositions containing and methods of using 1- aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives |
AU5772396A (en) | 1995-05-19 | 1996-11-29 | Chiroscience Limited | 3,4-disubstituted-phenylsulphonamides and their therapeutic use |
WO1997025983A1 (en) | 1996-01-22 | 1997-07-24 | Eli Lilly And Company | Indane derivatives for antipsychotic compositions |
US6083986A (en) | 1996-07-26 | 2000-07-04 | Icagen, Inc. | Potassium channel inhibitors |
US6048877A (en) | 1997-02-21 | 2000-04-11 | Bristol-Myers Squibb Company | Tetralone derivatives as antiarrhythmic agents |
-
1999
- 1999-01-13 US US09/229,315 patent/US6333337B1/en not_active Expired - Fee Related
- 1999-01-26 ZA ZA9900550A patent/ZA99550B/xx unknown
- 1999-01-27 HU HU0101269A patent/HUP0101269A3/hu unknown
- 1999-01-27 DE DE69916792T patent/DE69916792D1/de not_active Expired - Lifetime
- 1999-01-27 AT AT99902443T patent/ATE265426T1/de not_active IP Right Cessation
- 1999-01-27 PL PL99341859A patent/PL341859A1/xx not_active Application Discontinuation
- 1999-01-27 TW TW088101240A patent/TW542823B/zh not_active IP Right Cessation
- 1999-01-27 NZ NZ505666A patent/NZ505666A/xx unknown
- 1999-01-27 KR KR1020007008128A patent/KR20010034377A/ko not_active Application Discontinuation
- 1999-01-27 RU RU2000122451/04A patent/RU2218330C2/ru not_active IP Right Cessation
- 1999-01-27 AU AU22419/99A patent/AU745845B2/en not_active Ceased
- 1999-01-27 CA CA002317457A patent/CA2317457A1/en not_active Abandoned
- 1999-01-27 CN CN99804373A patent/CN1294577A/zh active Pending
- 1999-01-27 JP JP2000528531A patent/JP2002501041A/ja active Pending
- 1999-01-27 WO PCT/US1999/001663 patent/WO1999037607A1/en active IP Right Grant
- 1999-01-27 EP EP99902443A patent/EP1051394B1/en not_active Expired - Lifetime
- 1999-01-27 ID IDW20001654A patent/ID25853A/id unknown
- 1999-01-27 TR TR2000/02191T patent/TR200002191T2/xx unknown
- 1999-01-27 IL IL13721999A patent/IL137219A0/xx unknown
- 1999-01-27 BR BR9907236-0A patent/BR9907236A/pt not_active IP Right Cessation
-
2000
- 2000-07-13 NO NO20003600A patent/NO20003600L/no unknown
Also Published As
Publication number | Publication date |
---|---|
US6333337B1 (en) | 2001-12-25 |
NO20003600L (no) | 2000-09-26 |
ID25853A (id) | 2000-11-09 |
CN1294577A (zh) | 2001-05-09 |
ATE265426T1 (de) | 2004-05-15 |
PL341859A1 (en) | 2001-05-07 |
WO1999037607A1 (en) | 1999-07-29 |
ZA99550B (en) | 1999-07-26 |
EP1051394A1 (en) | 2000-11-15 |
IL137219A0 (en) | 2001-07-24 |
NO20003600D0 (no) | 2000-07-13 |
CA2317457A1 (en) | 1999-07-29 |
HUP0101269A3 (en) | 2003-01-28 |
DE69916792D1 (de) | 2004-06-03 |
RU2218330C2 (ru) | 2003-12-10 |
AU2241999A (en) | 1999-08-09 |
HUP0101269A1 (hu) | 2001-10-28 |
JP2002501041A (ja) | 2002-01-15 |
TW542823B (en) | 2003-07-21 |
KR20010034377A (ko) | 2001-04-25 |
TR200002191T2 (tr) | 2000-11-21 |
NZ505666A (en) | 2002-11-26 |
EP1051394B1 (en) | 2004-04-28 |
AU745845B2 (en) | 2002-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR9907236A (pt) | Inibidores de canais de potássio | |
BR9710587A (pt) | Inibidores de canal de potássio | |
BR0205829A (pt) | Novas aminas como ligantes dos receptores de histamina-3 e suas aplicações terapêuticas | |
WO1998004521B1 (en) | Potassium channel inhibitors | |
BR0111596A (pt) | Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças | |
BR9913255A (pt) | Composto, composição farmacêutica, processo de tratamento de uma condição de doença mediada por metaloproteinase, processo para preparar um composto, e, uso de um composto | |
DK0850221T3 (da) | Meta-guanidin-, urinstof-, thiourinstof- eller azacykliske aminobenzoesyrederivater som intergrinantagonister | |
BR0313234A (pt) | Composto, uso do mesmo, método de tratamento ou profilaxia de doenças, composição farmacêutica, e, processo para a preparação de um composto | |
DK1235826T3 (da) | Quinuclidinacrylamider | |
DK0889877T3 (da) | Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer | |
AR029301A1 (es) | Compuestos derivados de biarilo, metodos para su preparacion composiciones que los contienen, su uso como agonistas en receptores beta-adreno-receptores atipicos | |
DE69716449D1 (de) | Substituierte zyklische amine als metalloproteaseinhibitoren | |
DK0896533T3 (da) | Pentafluorbenzensulfonamider og analoger | |
BR0307351A (pt) | Composto, composição farmacêutica, método para tratar uma condição ou estado de doença mediados pela atividade de p38 quinase ou mediados por citocinas produzidas pela atividade de p38 quinase, uso de um composto, e, processo para preparar um composto | |
NO20045486L (no) | Nye forbindelser og deres anvendelse | |
NO20054787D0 (no) | Indenderivater som farmasotiske midler | |
BR0109235A (pt) | Derivados do ácido carboxìlico como antagonistas ip | |
BR9915403A (pt) | Antagonistas receptores iii de 4-aroil-piperidin-ccr-3 | |
UY25143A1 (es) | Procedimiento para la preparacion de inhibidores de proteasas. | |
HRP20050075B1 (hr) | Primjena specifiäśnog derivata cikliäśkog amina ili njegovih farmaceutski prihvatljivih soli u lijeäśenju ili prevenciji zatajenja srca | |
DK0808303T3 (da) | 5-(4-subst.-piperidinyl-1)-3-aryl-pentansyrederivater som tachykininreceptorantagonister | |
BR0308780A (pt) | Composto, processo para a preparação e uso do mesmo, método para o tratamento de um sujeito humano ou animal que sofre de, ou que é suscetìvel a, uma condição inflamatória, e, composição farmacêutica | |
DK1026170T3 (da) | Erythromycinderivater, fremgangsmåde til deres fremstilling og deres anvendelse som lægemidler | |
TR200001452T2 (tr) | Bifenilamidin türevleri. | |
CO4770955A1 (es) | Acidos 4-amino-2-heterobiciclo [3.1.0] hexano -4,6- dicarboxilicos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1945 DE 15 - 04 - 2008. |